Skip to main content

CORRECTION article

Front. Immunol., 13 December 2022
Sec. Multiple Sclerosis and Neuroimmunology
Volume 13 - 2022 | https://doi.org/10.3389/fimmu.2022.1095038

Corrigendum: Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of clinically defined MS from non-MS patients with CSF oligoclonal bands

This article is a correction to:

  1. Determination of CSF GFAP, CCN5, and vWF Levels Enhances the Diagnostic Accuracy of Clinically Defined MS From Non-MS Patients With CSF Oligoclonal Bands

    1. Read original article
Fay Probert*Fay Probert1*Tianrong Yeo,,Tianrong Yeo2,3,4Yifan Zhou,,Yifan Zhou2,5,6Megan SealeyMegan Sealey2Siddharth AroraSiddharth Arora7Jacqueline PalaceJacqueline Palace8Timothy D. W. ClaridgeTimothy D. W. Claridge1Rainer HillenbrandRainer Hillenbrand9Johanna OechteringJohanna Oechtering10Jens KuhleJens Kuhle10David LeppertDavid Leppert10Daniel C. Anthony*Daniel C. Anthony2*
  • 1Department of Chemistry, University of Oxford, Oxford, United Kingdom
  • 2Department of Pharmacology, University of Oxford, Oxford, United Kingdom
  • 3Department of Neurology, National Neuroscience Institute, Singapore, Singapore
  • 4Duke-National University of Singapore (NUS) Medical School, Singapore, Singapore
  • 5Translational Stem Cell Biology Branch, National Institutes of Health, Bethesda, MD, United States
  • 6Wellcome Medical Research Council (MRC) Trust Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom
  • 7Department of Mathematics, University of Oxford, Oxford, United Kingdom
  • 8Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
  • 9Biomarker Development, Novartis Pharma AG, Basel, Switzerland
  • 10Neurologic Clinic and Policlinic, Multiple Sclerosis (MS) Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Clinical Research and Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland

A Corrigendum on
Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of clinically defined MS from non-MS patients with CSF oligoclonal bands

by Probert F, Yeo T, Zhou Y, Sealey M, Arora S, Palace J, Claridge TDW, Hillenbrand R, Oechtering J, Kuhle J, Leppert D and Anthony DC (2022). Front. Immunol. 12:811351. doi: 10.3389/fimmu.2021.811351

In the published article, there was an error in the Data Availability statement which was: "The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material". The correct Data Availability statement appears below.

Data availability statement

The datasets presented in this article are not readily available because they contain identifiable information from human subjects that cannot be shared in open access repositories for legal reasons. Anonymized data will be shared upon request from any qualified investigator. Requests should be directed to the corresponding authors.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: diagnosis, metabolomics (OMICS), multiple sclerosis (MS), proteomics, oligoclonal band, biomarker

Citation: Probert F, Yeo T, Zhou Y, Sealey M, Arora S, Palace J, Claridge TDW, Hillenbrand R, Oechtering J, Kuhle J, Leppert D and Anthony DC (2022) Corrigendum: Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of clinically defined MS from non-MS patients with CSF oligoclonal bands. Front. Immunol. 13:1095038. doi: 10.3389/fimmu.2022.1095038

Received: 10 November 2022; Accepted: 11 November 2022;
Published: 13 December 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Probert, Yeo, Zhou, Sealey, Arora, Palace, Claridge, Hillenbrand, Oechtering, Kuhle, Leppert and Anthony. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Daniel C. Anthony, daniel.anthony@pharm.ox.ac.uk; Fay Probert, fay.probert@p harm.ox.ac.uk

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.